End-of-day quote
Casablanca S.E.
23:00:00 06/05/2024 BST
|
5-day change
|
1st Jan Change
|
981
MAD
|
-0.41%
|
|
-0.48%
|
-1.90%
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Capitalization
1 |
1,400
|
1,000
|
856
|
710
|
1,140
|
1,068
|
Enterprise Value (EV)
1 |
1,471
|
1,022
|
707.7
|
570.9
|
934.9
|
1,011
|
P/E ratio
|
-
|
25.8
x
|
16.4
x
|
11.8
x
|
16.5
x
|
14.2
x
|
Yield
|
-
|
-
|
-
|
-
|
3.51%
|
3.75%
|
Capitalization / Revenue
|
2.74
x
|
2.25
x
|
1.64
x
|
1.24
x
|
1.81
x
|
1.52
x
|
EV / Revenue
|
2.88
x
|
2.3
x
|
1.35
x
|
1
x
|
1.48
x
|
1.44
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-8,263,604
x
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-0%
|
Price to Book
|
-
|
3.67
x
|
2.64
x
|
1.85
x
|
2.69
x
|
2.33
x
|
Nbr of stocks (in thousands)
|
1,000
|
1,000
|
1,000
|
1,000
|
1,000
|
1,000
|
Reference price
2 |
1,400
|
1,000
|
856.0
|
710.0
|
1,140
|
1,068
|
Announcement Date
|
26/03/19
|
26/03/19
|
30/03/20
|
15/04/21
|
26/04/22
|
25/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net sales
1 |
511.2
|
444.5
|
522.5
|
573.2
|
630.5
|
704.6
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
102
|
54.72
|
91.24
|
101.5
|
104.9
|
134.1
|
Operating Margin
|
19.96%
|
12.31%
|
17.46%
|
17.7%
|
16.64%
|
19.03%
|
Earnings before Tax (EBT)
1 |
97.19
|
55.04
|
81.58
|
90.45
|
102.7
|
114.3
|
Net income
1 |
65.8
|
38.75
|
52.11
|
60.26
|
68.97
|
75.28
|
Net margin
|
12.87%
|
8.72%
|
9.97%
|
10.51%
|
10.94%
|
10.68%
|
EPS
|
-
|
38.75
|
52.11
|
60.26
|
68.97
|
75.28
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-122.4
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-17.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
40.00
|
40.00
|
Announcement Date
|
26/03/19
|
26/03/19
|
30/03/20
|
15/04/21
|
26/04/22
|
25/04/23
|
Fiscal Period: December |
2017
|
2018
|
2019
|
2020
|
2021
|
2022
|
---|
Net Debt
1 |
70.8
|
22.4
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
-
|
-
|
148
|
139
|
205
|
56.8
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-122
|
ROE (net income / shareholders' equity)
|
24%
|
15.3%
|
17.5%
|
17%
|
17.1%
|
17.1%
|
ROA (Net income/ Total Assets)
|
13.6%
|
7.36%
|
11.7%
|
12.3%
|
11.3%
|
12.2%
|
Assets
1 |
484.4
|
526.2
|
444.1
|
491.8
|
610.7
|
619.3
|
Book Value Per Share
|
-
|
272.0
|
324.0
|
385.0
|
424.0
|
459.0
|
Cash Flow per Share
|
-
|
26.60
|
119.0
|
104.0
|
160.0
|
106.0
|
Capex
|
-
|
-
|
-
|
-
|
-
|
129
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
18.29%
|
Announcement Date
|
26/03/19
|
26/03/19
|
30/03/20
|
15/04/21
|
26/04/22
|
25/04/23
|
|
1st Jan change
|
Capi.
|
---|
| -1.90% | 94.19M | | +19.62% | 43.27B | | +24.52% | 22.92B | | +20.29% | 15.43B | | +7.48% | 12.95B | | +42.51% | 11.83B | | -8.84% | 6.91B | | -0.05% | 6.79B | | -8.87% | 5.73B | | +13.13% | 5.55B |
Generic Pharmaceuticals
|